Dynavax Technologies Corporation news

   Watch this stock
Showing stories 1 - 5 of about 5   

Articles published

DVAX 22.35 -0.08 (-0.36%)
price chart
85% Probability Of FDA Approval For Dynavax's Heplisav, Says Cowen's Senior ...
One of them is Dynavax Technologies (NASDAQ:DVAX), a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious and inflammatory diseases.
6 Stocks Trading Under $5 on Winning Streaks
Dynavax Technologies Corporation (DVAX, Earnings, Analysts, Financials): A clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases.
Related articles »  
Risk Vs. Reward Never Gets Old
Everything one needs for a wild ride in a biotech company. The reason I like ... Dynavax Technologies has a number of promising drugs, with HEPLISAVTM being their prize, as it treats Hepatitis B, which afflicts 350 million people worldwide.
Biodefense Industry - Market to Benefit from Federal Funding such as the BIO ...
7.2.1 Biodefense Contracts 31. 7.3 Bavarian Nordic 32. 7.3.1 Biodefense Contracts 32. 7.4 Cleveland BioLabs 33. 7.4.1 Biodefense Contracts 33.
Gains in Employment Likely As Good As It Gets?
Insider Trading 19 October 2012: Dynavax Technologies Big Seller This Week · GE Issues Stern Warning Words to France · Vehicle Traffic Volumes .... 27Mar2015 Pre-Market Commentary: Markets Expected To Open Lower, Oil Prices Falling, U.S. Dollar Resumes ...
Related articles »